We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
6 result(s) found, displaying 1 to 6
-
Australian public assessment report (AusPar)Idefirix (imlifidase) has been approved for the desensitisation treatment of highly sensitised adult kidney transplant candidates prior to kidney transplantation
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IDEFIRIX imlifidase 11 mg powder for concentrate for solution for infusion.
-
Prescription medicine decision summaryTGA decision: Idefirix (imlifidase) has provisional approval for desensitisation treatment of adult kidney transplant candidates.
-
Prescription medicine registrationActive ingredients: imlifidase.
-
Designation or determinationOrphan drug
-
Designation or determinationProvisional determination